AIMS: To review the management of Wilms' tumour. METHODS: A search of the literature was performed using the PubMed database (1966 to May 2006) with the search terms 'Wilms' and either 'tumour/tumor' or 'cancer' or 'carcinoma'. This was augmented by manual searches of publications. FINDINGS: The success of clinical trials in Wilms' tumour patients over the past 30 years has led to an overall survival of 85% and the introduction of less aggressive chemotherapeutic regimes for patients. Large randomised controlled trials have been published on the management of Wilms' tumour by various collaborative groups, including the National Wilms' Tumour Study Group (NWTSG) in North America and the Société Internationale d'Oncologie Pédiatrique (SIOP) plus the United Kingdom Children's Cancer Study Group (UKCCSG) in Europe. CONCLUSIONS: Controversy exists as to the best approach to the management of these children with regard to neoadjuvant chemotherapy. Challenges remain in the identification of histological and molecular risk factors for the stratification of treatment intensity.
AIMS: To review the management of Wilms' tumour. METHODS: A search of the literature was performed using the PubMed database (1966 to May 2006) with the search terms 'Wilms' and either 'tumour/tumor' or 'cancer' or 'carcinoma'. This was augmented by manual searches of publications. FINDINGS: The success of clinical trials in Wilms' tumour patients over the past 30 years has led to an overall survival of 85% and the introduction of less aggressive chemotherapeutic regimes for patients. Large randomised controlled trials have been published on the management of Wilms' tumour by various collaborative groups, including the National Wilms' Tumour Study Group (NWTSG) in North America and the Société Internationale d'Oncologie Pédiatrique (SIOP) plus the United Kingdom Children's Cancer Study Group (UKCCSG) in Europe. CONCLUSIONS: Controversy exists as to the best approach to the management of these children with regard to neoadjuvant chemotherapy. Challenges remain in the identification of histological and molecular risk factors for the stratification of treatment intensity.
Authors: Sang Hun Lee; Min Ho Bae; Sung Ho Choi; Jin Seok Lee; Young Sam Cho; Kwan Joong Joo; Chil Hun Kwon; Heung Jae Park Journal: Korean J Urol Date: 2012-08-16
Authors: Ana Maria Rabelo de Carvalho; Luciana Resende Bandeira de Melo; Vera Lúcia Moraes; Rejane Pereira Neves Journal: Braz J Microbiol Date: 2008-03-01 Impact factor: 2.476
Authors: Ossama M Zakaria; Emad N Hokkam; Karam Al Sayem; Mohamed Yasser I Daoud; Hazem M Zakaria; Fouad Sedky; Seba H Graiz; Saleh A Moussa; Hamed A Al Wadaani Journal: World J Oncol Date: 2015-10-26